The anaplastic lymphoma kinase testing conundrum

Expert Review of Molecular Diagnostics

Volumn 15, Issue 2, 2015, Pages 161-163

  Conde, Esther ^a   Taniere, Philippe ^b   Lopez Rios, Fernando ^a  

^a Hospital Universitario HM Sanchinarro   (Spain)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ALK; companion diagnostics; FISH; IHC; lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; TUMOR MARKER;

HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NEXT GENERATION SEQUENCING; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SQUAMOUS CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84921366213     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.997713     Document Type: Review

References (20)

1. Fan L, Feng Y, Wan H, et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-Analysis. PLoS One 2014;9:e100866
2. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
3. Conde E, Angulo B, Izquierdo E, et al. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology 2013;62:609-16
4. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50
5. Riely GJ, Chaft JE, Ladanyi M, et al. Incorporation of crizotinib into de NCCN guidelines. J Natl Compr Can Netw 2011;9:1328-30
6. European Medicines Agency. Available from: www.ema.europa.eu/docs/en-GB/.document-library/.EPAR-Public-assessment-report/human/.002489/WC500134761.pdf [Last accessed on 21 July 2013]
7. FDA granted accelerated approval to ceritinib (ZYKADIA, Novartis Pharmaceuticals Corporation). Available from: www.fda.gov/Drugs/.InformationOnDrugs/ApprovedDrugs/.ucm395386.htm [Last accessed on 30 April 2014]
8. Gridelli C, Solange P, Sgambato A, et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014;40:300-6
9. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137: 828-60
10. Hirsch FR, Bunn PA Jr, Herbse RS. 'Companion diagnostics': has their time come and gone?. Clin Cancer Res 2014;20: 4422-4
11. FDA clears BioView Duet- system for automated ALK FISH scanning of lung cancer tissue specimens. Available from: www.bioview.co.il/htmls/page-70.aspx?. c0=12677&bsp=12624 [Last accessed on June 2014]
12. Conde E, Suárez-Gauthier A, Benito A, et al. Accurate Identification of ALK Positive Lung Carcinoma Patients: novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS One 2014;9:e107200
13. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014;9: 631-8
14. Zwaenepoel K, Van Dongen A, Lambin S, et al. Detection of ALK expression in NSCLC with ALK-gene rearrangements-comparison of multiple IHC methods. Histopathology 2014;65(4):539-48
15. Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014;9:295-306
16. AmoyDx- Lung Cancer Therapeutic Target Identification Solution. Available from: www.amoydx.com//en/product/products-99. html
17. Ion AmpliSeq- Colon and Lung Cancer Research Panel v2 and Ion AmpliSeq- RNA Fusion Lung Cancer Research Panel. Available from: https://tools.lifetechnologies. com/content/sfs/brochures/AmpliSeq-Colon-Lung-Cancer-Panel-Flyer.pdf
18. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012;7:e14-16
19. Salto-Tellez M, Gonzalez de Castro D. Next-generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol 2014;234:5-10
20. Conde E, Angulo B, Izquierdo E, et al. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol 2013;15:503-8